Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      Home/Our innovation /Focus areas/Neuroscience/Specialty ophthalmology/Taking on GA and Dry AMD

      Taking on GA and Dry AMD

      Share Article
      Share to

      - AMD is the leading cause of vision loss among older adults

      - As of 2020, ~200 million people worldwide are affected by AMD

      Age-related macular degeneration (AMD) is the deterioration of the retina and choroid that leads to a substantial loss in sharpness of vision. Yellow deposits under the retina are called drusen, and having them may increase a person’s risk of developing AMD.

      AMD is classified as early AMD, intermediate AMD, and advanced AMD. A large number of drusen being present in the eye is an important indicator of early AMD.

      JJ_Photo_Grandmother laughing with granddaughter_Offset_819359_4Star.jpg

      Geographic atrophy (GA), a late-stage and severe form of AMD, is a multifactorial and complex disease, associated with inflammation and oxidative stress, which causes atrophy of the macula.

      GA is a progressive and irreversible condition affecting over 5 million patients globally and leads to significant central vision loss and blindness:

      • GA is a leading cause of blindness in people over 65 years of age.   
      • As life expectancy increases, this burden will become greater in the foreseeable future and negatively impact patient independence.

      Johnson & Johnson is exploring novel class therapies, including a gene therapy for the treatment of geographic atrophy.